Efficacy of docetaxel addition to next‐generation androgen receptor‐axis‐targeted therapies and androgen deprivation therapy in metastatic hormone‐sensitive prostate cancer: A tumor volume‐specific analysis

Patients with mHSPC did not show significant improvement with docetaxel addition to ARAT-based regimens, regardless of tumor volume. Further research is needed to identify potential beneficiaries of this combination therapy.